Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: C7

Gene summary for C7

Gene summary.

Gene information	Species	Human
	Gene symbol	C7
	Gene ID	730
	Gene name	complement C7
	Gene Alias	C7
	Cytomap	5p13.1
	Gene Type	protein-coding
	GO ID	GO:0002250
	UniProtAcc	P10643

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
730	C7	S41	Human	Liver	Cirrhotic	1.84e-05	9.56e-01	-0.0343
730	C7	S43	Human	Liver	Cirrhotic	8.05e-08	7.04e-01	-0.0187
730	C7	cirrhotic3	Human	Liver	Cirrhotic	3.02e-16	5.44e-01	0.0215
730	C7	HCC1	Human	Liver	HCC	4.11e-03	2.49e-01	0.5336

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Liver		HCC: Hepatocellular carcinoma
Liver		NAFLD: Non-alcoholic fatty liver disease

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:000940820	Skin	AK	response to heat	29/1910	110/18723	1.18e-06	3.73e-05	29
GO:00073699	Skin	AK	gastrulation	41/1910	185/18723	1.32e-06	4.13e-05	41
GO:000155820	Skin	AK	regulation of cell growth	73/1910	414/18723	2.21e-06	6.27e-05	73
GO:19019907	Skin	AK	regulation of mitotic cell cycle phase transition	57/1910	299/18723	2.47e-06	6.76e-05	57
GO:00063549	Skin	AK	DNA-templated transcription, elongation	25/1910	91/18723	2.82e-06	7.60e-05	25
GO:003460524	Skin	AK	cellular response to heat	21/1910	69/18723	2.93e-06	7.82e-05	21
GO:00017045	Skin	AK	formation of primary germ layer	30/1910	121/18723	3.12e-06	8.17e-05	30
GO:000645726	Skin	AK	protein folding	44/1910	212/18723	3.54e-06	8.91e-05	44
GO:19019877	Skin	AK	regulation of cell cycle phase transition	69/1910	390/18723	3.69e-06	9.11e-05	69
GO:20000457	Skin	AK	regulation of G1/S transition of mitotic cell cycle	33/1910	142/18723	4.71e-06	1.12e-04	33
GO:00327867	Skin	AK	positive regulation of DNA-templated transcription, elongation	12/1910	27/18723	4.93e-06	1.16e-04	12
GO:004578716	Skin	AK	positive regulation of cell cycle	58/1910	313/18723	5.08e-06	1.19e-04	58
GO:190370625	Skin	AK	regulation of hemopoiesis	65/1910	367/18723	6.74e-06	1.52e-04	65
GO:006107725	Skin	AK	chaperone-mediated protein folding	20/1910	67/18723	6.97e-06	1.55e-04	20
GO:00063688	Skin	AK	transcription elongation from RNA polymerase II promoter	20/1910	69/18723	1.14e-05	2.37e-04	20
GO:005086317	Skin	AK	regulation of T cell activation	59/1910	329/18723	1.20e-05	2.46e-04	59
GO:000645825	Skin	AK	'de novo' protein folding	15/1910	43/18723	1.21e-05	2.46e-04	15
GO:000715919	Skin	AK	leukocyte cell-cell adhesion	64/1910	371/18723	1.87e-05	3.52e-04	64
GO:00074927	Skin	AK	endoderm development	21/1910	77/18723	1.95e-05	3.64e-04	21
GO:19028066	Skin	AK	regulation of cell cycle G1/S phase transition	35/1910	168/18723	3.11e-05	5.26e-04	35

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0517122	Liver	Cirrhotic	Coronavirus disease - COVID-19	136/2530	232/8465	3.28e-20	1.82e-18	1.12e-18	136
hsa046102	Liver	Cirrhotic	Complement and coagulation cascades	48/2530	86/8465	4.41e-07	5.44e-06	3.35e-06	48
hsa0481021	Liver	Cirrhotic	Regulation of actin cytoskeleton	100/2530	229/8465	5.28e-06	5.50e-05	3.39e-05	100
hsa0517132	Liver	Cirrhotic	Coronavirus disease - COVID-19	136/2530	232/8465	3.28e-20	1.82e-18	1.12e-18	136
hsa046103	Liver	Cirrhotic	Complement and coagulation cascades	48/2530	86/8465	4.41e-07	5.44e-06	3.35e-06	48
hsa0481031	Liver	Cirrhotic	Regulation of actin cytoskeleton	100/2530	229/8465	5.28e-06	5.50e-05	3.39e-05	100
hsa0502022	Liver	HCC	Prion disease	195/4020	273/8465	3.26e-16	1.56e-14	8.67e-15	195
hsa0517142	Liver	HCC	Coronavirus disease - COVID-19	167/4020	232/8465	1.50e-14	4.19e-13	2.33e-13	167
hsa046104	Liver	HCC	Complement and coagulation cascades	57/4020	86/8465	3.19e-04	1.45e-03	8.04e-04	57
hsa0481041	Liver	HCC	Regulation of actin cytoskeleton	134/4020	229/8465	4.48e-04	1.94e-03	1.08e-03	134
hsa0502032	Liver	HCC	Prion disease	195/4020	273/8465	3.26e-16	1.56e-14	8.67e-15	195
hsa0517152	Liver	HCC	Coronavirus disease - COVID-19	167/4020	232/8465	1.50e-14	4.19e-13	2.33e-13	167
hsa046105	Liver	HCC	Complement and coagulation cascades	57/4020	86/8465	3.19e-04	1.45e-03	8.04e-04	57
hsa0481051	Liver	HCC	Regulation of actin cytoskeleton	134/4020	229/8465	4.48e-04	1.94e-03	1.08e-03	134

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

SNV

Missense_Mutation

c.2353N>C

p.Glu785Gln

p.E785Q

P10643

protein_coding

tolerated(1)

benign(0)

TCGA-A2-A0YK-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

SNV

Missense_Mutation

c.320C>T

p.Ser107Phe

p.S107F

P10643

protein_coding

tolerated(0.21)

possibly_damaging(0.77)

TCGA-AN-A0XW-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

SNV

Missense_Mutation

rs376674018

c.148N>T

p.Arg50Trp

p.R50W

P10643

protein_coding

deleterious(0)

probably_damaging(0.991)

TCGA-AO-A03T-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cyclophosphamide

SNV

Missense_Mutation

c.1639N>C

p.Asp547His

p.D547H

P10643

protein_coding

deleterious(0)

probably_damaging(0.966)

TCGA-C8-A12P-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

SNV

Missense_Mutation

c.2037G>C

p.Trp679Cys

p.W679C

P10643

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-D8-A1JK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

SNV

Missense_Mutation

c.944T>C

p.Val315Ala

p.V315A

P10643

protein_coding

tolerated(0.31)

benign(0.207)

TCGA-D8-A1XK-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicine+cyclophosphamide

SNV

Missense_Mutation

rs766182545

c.2353N>A

p.Glu785Lys

p.E785K

P10643

protein_coding

tolerated(0.07)

benign(0.003)

TCGA-D8-A27G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

SNV

Missense_Mutation

novel

c.2451N>T

p.Glu817Asp

p.E817D

P10643

protein_coding

deleterious(0.01)

probably_damaging(0.971)

TCGA-GI-A2C9-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

insertion

Frame_Shift_Ins

novel

c.1744_1745insGCATTAATCAGTATCTCTTGACTGAGGAAGC

p.Val582GlyfsTer14

p.V582Gfs*14

P10643

protein_coding

TCGA-AN-A0FV-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

insertion

In_Frame_Ins

novel

c.2350_2350+1insCTCTGA

p.Ala784_Glu785insLeuThr

p.A784_E785insLT

P10643

protein_coding

TCGA-AR-A0U0-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1